Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 94Carcinoma, Ovarian Epithelial 43Fallopian Tube Neoplasms 41Uterine Cervical Neoplasms 26Endometrial Neoplasms 8Neoplasms 7Recurrence 5Neoplasm Metastasis 5Small Cell Lung Carcinoma 3Lung Neoplasms 3Brenner Tumor 3Vaginal Neoplasms 2Uterine Neoplasms 2Uterine Cervical Dysplasia 2Sarcoma 2Peritoneal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Wilms Tumor 1Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Retinoblastoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Melanoma 1Lymphoma 1

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Topotecan × Gynecologic × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡